WALDENSTROM’S MACROGLOBULINEMIA

MYD88 p.(Leu265Pro) Variant

The MYD88 p.(Leu265Pro) variant has been reported in 91% of patients with Waldenström’s Macroglobulinaemia (Treon 2012 NEJM 367: 826-833). The MYD88 p.(Leu265Pro) variant has also been reported in splenic marginal zone lymphoma (15%) (Martinz-Lopez 2015 Am J Surg Pathol 39(5) 644-51), activated B-cell-type diffuse large B-cell lymphoma (14%-29%), primary central nervous system lymphoma (33%), mucosa-associated lymphoid tissue lymphoma (9%), chronic lymphocytic leukaemia (2.9%) (Yang 2013 Blood 122 (7): 1222-1232), primary cutaneous large B-cell lymphoma, leg type (61%) (Pham-Ledard 2014 Modern Pathology 27: 402-411) and vitreoretinal diffuse B-cell lymphoma (Bonzheim 2015 126 (1) 76-79).

Laboratory contact: Dr. Caroline Wickham 01392 408248 caroline.wickham@nhs.net

Clinical contact: Dr. Paul Kerr 01392 402917 paul.kerr1@nhs.net